Paradigm Therapeutics Recognized Again for Innovative Therapy in Epidermolysis Bullosa Treatment
Paradigm Therapeutics Recognized Again for Innovative Therapy in Epidermolysis Bullosa Treatment
On October 13, 2026, Paradigm Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to addressing rare diseases, proudly announced its second nomination for the prestigious Prix Galien USA
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.